GAPDHP2

Across TCGA pan-cancer cohorts, GAPDHP2 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated GAPDHP2 data layer.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GAPDHP2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated GAPDHP2 expression acts as an unfavorable survival marker, although some lineages such as LUSC and LAML show a favorable association.

LUSC, KIRP, and LAML are the cancer types where GAPDHP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Quartile	II,III,IV	0.654	0.377	<.001	31	view →
KIRP	DFS	Median	All	0.358	0.760	<.001	31	view →
LAML	DFS	Quartile	All	0.590	0.290	.003	18	view →
LGG	DFS	Tertile	All	0.728	0.902	<.001	17	view →
LIHC	OS	Median	All	0.712	0.837	.011	16	view →
SARC	DFS	Tertile	All	0.167	0.399	<.001	15	view →
BRCA	DFS	Median	III,IV	0.853	0.731	.006	14	view →
THCA	OS	Quartile	All	0.944	1.000	.002	13	view →
CESC	OS	Quartile	All	0.887	0.721	.005	12	view →
CHOL	DFS	Tertile	III,IV	0.095	0.779	.024	12	view →
SKCM	OS	Quartile	III,IV	0.800	0.585	.002	11	view →
MESO	OS	Median	II,III,IV	0.492	0.632	.023	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

GAPDHP2–LUSC (DFS)

Open the LUSC breakdown →